A Phase 1 interventional study of DONQ52 and Placebo in Celiac Disease, sponsored by Chugai Pharmaceutical. Completed at 21 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-01-31.
Sponsored by Chugai Pharmaceutical (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 103 studies in Celiac Disease with a site in United States — 16 open to participants now, 20 under way, none of them phase 3. Celiac Disease · United States.
Among the 103 studies in Celiac Disease with a site in United States, this one is the 31st largest by enrollment of the 68 interventional ones that give a count, is one of 8 that started in 2022, is one of 16 in phase 1, and was the 83rd registered.
352 studies on the registry are indexed under Celiac Disease; 77 are open to participants now.
Browse Celiac Disease studies →16 of the 103 studies in Celiac Disease with a site in United States are open now. Recruiting first, the newest first:
Nielsen Fernandez-Becker · Sites in United States
Ages 18+
Chugai Pharmaceutical · Sites in United States, Australia, New Zealand
Ages 18–75
Joined Bio · Sites in United States
Ages 18–90 · Healthy volunteers
Columbia University · Sites in United States
Ages 18–75
Luventix, Inc. · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 48 Celiac Disease studies recruiting now, 24 (50%) set no upper age limit and 19 (40%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
103 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 22 · Phase 3 2 · Phase 4 2
First in 1995; this study’s year is marked. 8 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 56 is above the median of 50 across 214 interventional studies indexed under Celiac Disease.
Median enrollment 46 across the 68 interventional studies, 175 across the 35 observational. Of the 74 that completed or were terminated, 17 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 103 have an industry lead sponsor. The 10 most frequent:
This study is registered under Chugai Pharmaceutical, one of the names counted as Hoffmann-La Roche. Under that name alone:
Chugai Pharmaceutical is the lead sponsor of 63 studies on the registry; 7 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Hoffmann-La Roche has 4 studies filed under Celiac Disease — fewer than ten, so there is no comparison to draw.
7 of the studies in Celiac Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06310291Barinthus BiotherapeuticsVTP-1000 in Adults With Celiac Disease | 2026-11 |
| NCT06908057AdventHealth Translational Research InstituteAccessing Care, Clinical Trials and Screening for Underserved Children and Adults With Type 1 Diabetes (ACCESS-T1D) | 2026-12 |
| NCT05680012University of ChicagoTissue Destruction and Healing in Celiac Disease | 2027-05-01 |
| NCT07377565Nielsen Fernandez-BeckerA First-in-Patient Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease | 2027-06-01 |
| NCT07239336Chugai PharmaceuticalStudy of DONQ52 in Active Celiac Disease | 2027-06-15 |
Add all 7 to your calendar (.ics) → With an account.
Among the 103 studies in Celiac Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is to characterize the safety and tolerability of an investigational drug called DONQ52 and consists of a single ascending dose part (Part A) and a multiple ascending dose part (Part B) in well-controlled celiac disease patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All randomized patients will receive one dose of either DONQ52 Dose A or placebo
Drug: DONQ52 · Drug: Placebo
All randomized patients will receive one dose of either DONQ52 Dose B or placebo
Drug: DONQ52 · Drug: Placebo
All randomized patients will receive one dose of either DONQ52 Dose C or placebo
Drug: DONQ52 · Drug: Placebo
All randomized patients will receive one dose of either DONQ52 Dose D or placebo
Drug: DONQ52 · Drug: Placebo
All randomized patients will receive multiple dose of either DONQ52 Dose E or placebo
Drug: DONQ52 · Drug: Placebo
All randomized patients will receive multiple dose of either DONQ52 Dose F or placebo
Drug: DONQ52 · Drug: Placebo
All randomized patients will receive multiple dose of either DONQ52 Dose G or placebo
Drug: DONQ52 · Drug: Placebo
Subcutaneous (SC) injection
Subcutaneous (SC) injection
Incidence and severity of treatment-emergent adverse events (TEAEs) as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 or higher
Incidence and severity of TEAEs and its relationship to the study drugs
Time frame: Up to 246 days
Safety as assessed by Vital signs (blood pressure, body temperature, pulse rate, respiratory rate, percutaneous oxygen saturation)
Abnormality in vital signs
Time frame: Up to 246 days
Safety as assessed by Electrocardiograms (ECGs; QT interval, heart rate)
Abnormality in Electrocardiograms (ECGs)
Time frame: Up to 246 days
Safety as assessed by Laboratory tests (hematology, blood chemistry, coagulation and urinalysis)
Incidence of laboratory abnormalities, based on clinical laboratory tests
Time frame: Up to 246 days
Pharmacokinetics; Serum DONQ52 concentration
Serum DONQ52 concentrations over time
Time frame: Up to 246 days
Pharmacokinetics; Maximum serum concentration [Cmax]
Cmax of DONQ52
Time frame: Up to 246 days
Pharmacokinetics; Time to maximum serum concentration [Tmax]
Tmax of DONQ52
Time frame: Up to 246 days
Pharmacokinetics; Area under the serum concentration time curve [AUC]
AUC of DONQ52
Time frame: Up to 246 days
Pharmacokinetics; Half life [T1/2]
T1/2 of DONQ52
Time frame: Up to 246 days
Immunogenicity
Prevalence and incidence of anti-drug antibodies (ADAs) to DONQ52
Time frame: Up to 246 days
Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform. For further details on Chugai's Data Sharing Policy and how to request access to related clinical study documents, see here (www.chugai-pharm.co.jp/english/profile/rd/ctds_request.html).
No publications or documents are linked to this record.
Ran from Sep 2022 to primary completion in Aug 2024, 22 months.
Of 14 phase 1 interventional studies under Celiac Disease, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 22 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.